Prediction of nonSVR to therapy with pegylated interferon-α2a and ribavirin in chronic hepatitis C genotype 1 patients after 4, 8 and 12 weeks of treatment

Journal of Viral Hepatitis

Volumn 17, Issue 5, 2010, Pages 345-351

  Lukasiewicz, E ^a,c   Gorfine, M ^b   Freedman, L S ^c   Pawlotsky, J M ^d   Schalm, S W ^e   Ferrari, C ^f   Zeuzem, S ^g   Neumann, A U ^a  

^a BAR ILAN UNIVERSITY   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c GERTNER INSTITUTE FOR EPIDEMIOLOGY AND HEALTH POLICY RESEARCH   (Israel)

^d HENRI MONDOR HOSPITAL   (France)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f UNIVERSITY HOSPITAL OF PARMA   (Italy)

^g SAARLAND UNIVERSITY   (Germany)

Author keywords

Combined therapy; Cross validation; Early viral kinetics; Genotype 1 hepatitis C virus; Prediction of nonsustained virological response

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ACCURACY; ADULT; ALGORITHM; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; GENDER; GROUPS BY AGE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PERFORMANCE; PREDICTION; PREDICTIVE VALIDITY; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGE FACTORS; ANTIVIRAL AGENTS; BODY MASS INDEX; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; MODELS, STATISTICAL; POLYETHYLENE GLYCOLS; PROGNOSIS; RIBAVIRIN; RNA, VIRAL; SEX FACTORS; TIME FACTORS; TREATMENT FAILURE; VIRAL LOAD;

EID: 77949754386     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2009.01183.x     Document Type: Article

References (33)

1. Hadziyannis S, Sette HJ, Morgan T. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004 140 : 346 355.
2. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 347 : 975 982.
3. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001 358 : 958 965.
4. Wong JB, Davis GL, McHutchison JG, Manns MP, Albrecht JK. Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C. Am J Gastroenterol 2003 98 : 2354 2362.
5. Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996 24 : 38 47.
6. McHutchison JG, Gordon SC, Schiff ER et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998 339 : 1485 1492.
7. Poynard T, Marcellin P, Lee SS et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998 352 : 1426 1432.
8. Foster G, Fired MW, Hadziyannis S et al. Treatment of chronic hepatitis C with peginterferon alfa 2a; patient age has a marked influence on the individual estimated probability of achieving a sustained virological response. Hepatology 2003 38 : 246A.
9. Lee SS, Heathcote EJ, Reddy KR et al. Prognostic factors and early predictability of sustained viral; response with peginterferon alfa-2a (40 KD). J Hepatol 2002 37 : 500 506.
10. Romero-Gómez M, Del Mar Viloria M, Andrade RJ et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005 128 : 636 641.
11. Neumann AU, Lam NP, Dahari H et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998 282 : 103 107.
12. Zeuzem S, Lee JH, Franke A, Rüster B, Prümmer O, Hermann G. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alpha. Hepatology 1998 27 : 1149 1156.
13. Ferenci P. Predicting the therapeutic response in patients with chronic hepatitis C: the role of viral kinetics studies. J Antimicrob Chemother 2004 53 : 15 18.
14. Lee WM, Reddy KR, Tong MJ et al. Early hepatitis C virus RNA response predicts interferon treatment outcomes in chronic hepatitis C. Hepatology 1998 28 : 1411 1415.
15. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with pegylated interferon a-2b and ribavirin in patients with chronic hepatitis C. Hepatology 2003 38 : 645 652.
16. National Institutes of Health. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002 - June 10-12, 2002. Hepatology 2002 36 (Suppl. 1 S3 20.
17. Ferenci P, Fried MW, Shiffman ML et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD)/ribavirin. J Hepatol 2005 43 : 425 433.
18. Jensen DM, Morgan TR, Marcellin P et al. Early identification of HCV gen 1 patients responding to 24 weeks peginterferon α-2a (40kd)/ribavirin therapy. Hepatology 2006 43 : 954 960.
19. Zeuzem S, Buti M, Ferenci P et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with gen 1 and low pretreatment viremia. J Hepatol 2006 44 : 97 103.
20. Castro FJ, Esteban JI, Juarez A et al. Early detection of nonresponse to interferon plus ribavirin combination treatment of chronic hepatitis C. J Viral Hepat 2002 9 : 202 207.
21. Yu JW, Wang GQ, Sun LJ, Li XG, Li SC. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin. J Gastroenterol Hepatol 2007 22 : 832 836.
22. Zeuzem S, Pawlotsky JM, Lukasiewicz E et al. DITTO-HCV Study Group. International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. J Hepatol 2005 43 : 250 257.
23. Tomasko L, Helms RW, Snapinn SM. A discriminant analysis extension to mixed models. Stat Med 1999 18 : 1249 1260.
24. Dodd LE, Pepe MS. Partial AUC estimation and regression. Biometrics 2003 59 : 614 623.
25. McClish DK. Analysing a portion of the ROC curve. Med Decis Making 1989 9 : 190 195.
26. Efron B. The Jackknife, the Bootstrap and Other Resampling Plans. Philadelphia : SIAM, 1982.
27. Shao J, Tu D. The Jackknife and Bootstrap. New York : Springer, 1995.
28. Spiegelhalter DJ, Abrams KR, Myles JP. Randomized controlled trials. (eds) : Bayesian Approaches to Clinical Trials and Health-Care Evaluation. Chichester : John Wiley & Sons Ltd, 2004 : 184 186.
29. Neumann AU, Lukasiewicz (Hagai) E, Schalm SW et al. Early viral kinetics prediction of sustained virological response after 1 or 4 weeks of peg-interferon-alfa-2a and ribavirin therapy (DITTO-HCV project). Hepatology 2003 38 : 248.
30. Cohen J. The cost of dichotomization. Appl Psychol Meas 1983 7 : 249 253.
31. McCallum RC, Zhang S, Preacher KJ, Rucker DD. On the practice of dichotomization of quantitative variables. Psychol Methods 2002 7 : 19 40.
32. Charlson ME, Ales KL, Simon R, MacKenzie CR. Why predictive indexes perform less well in validation studies: is it magic or methods? Arch Intern Med 1987 147 : 2155 2161.
33. Steyerberg EW, Bleeker SE, Moll HA, Grobbee DE, Moons KG. Internal and external validation of predictive models: a simulation study of bias and precision in small samples. J Clin Epidemiol 2003 56 : 441 447.